Dashboard
Manage Tickers

PHIO Phio Pharmaceuticals Corp.

Nasdaq phiopharma.com


$ 2.17 $ 0.04 (1.88 %)    

Tuesday, 14-Oct-2025 10:52:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 596.92 $ 1.69 (0.28 %)
DIA $ 460.54 $ 3.53 (0.77 %)
SPY $ 660.13 $ 2.83 (0.43 %)
TLT $ 90.63 $ -0.01 (-0.01 %)
GLD $ 380.97 $ 2.67 (0.71 %)
$ 2.18
$ 2.12
$ 2.15 x 130
$ 2.20 x 248
$ 2.12 - $ 2.17
$ 0.97 - $ 9.79
70,864
na
12.48M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-22-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-27-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-26-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-30-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

phio-pharma-to-present-update-on-proprietary-intasyl-sirna-technology-and-progress-on-on-going-clinical-trial-with-lead-compound-ph-762-for-treatment-of-skin-cancers
Phio Pharma To Present Update On Proprieta...
09/23/2025 11:50:15

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...

phio-pharma-to-present-ph-762-intasyl-sirna-skin-cancer-trial-progress-and-strategic-outlook-at-life-sciences-future-conference-sept-25-26-2025
Phio Pharma To Present PH-762 INTASYL siRN...
09/18/2025 11:48:35

Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prus...

phio-pharmaceuticals-to-discuss-strategy-for-ph-762-skin-cancer-drug-at-investor-conference
Phio Pharmaceuticals to Discuss Strategy f...
09/03/2025 11:51:41

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its propri...

phio-pharmaceuticals-has-been-issued-canadian-patent-number-3027780-titled-reduced-size-self-delivering-rnai-compounds
Phio Pharmaceuticals Has Been Issued Canad...
09/02/2025 19:58:46

https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3027780/summary.html

hc-wainwright--co-reiterates-buy-on-phio-pharma-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Phio...
08/15/2025 11:17:14

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.

phio-pharma-q2-eps-045-misses-036-estimate
Phio Pharma Q2 EPS $(0.45) Misses $(0.36) ...
08/14/2025 20:19:55

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36)...

phio-pharmaceuticals-announces-25m-in-gross-proceeds-from-exercise-of-928596-warrants-at-200-and-2485-per-share-and-issues-1857192-new-unregistered-warrants-at-2485
Phio Pharmaceuticals Announces $2.5M In Gr...
07/25/2025 19:07:55

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
07/25/2025 17:07:15

phio-pharmaceuticals-reports-complete-tumor-clearance-in-cscc-patient-and-partial-response-in-stage-4-merkel-cell-carcinoma-in-ongoing-ph-762-phase-1b-trial
Phio Pharmaceuticals Reports Complete Tumo...
07/25/2025 16:40:26

Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cel...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
07/25/2025 12:08:49

phio-pharmaceuticals-announces-comprehensive-us-drug-substance-development-services-agreement-for-lead-compound-ph762
Phio Pharmaceuticals Announces Comprehensi...
07/25/2025 11:47:08

hc-wainwright--co-reiterates-buy-on-phio-pharma-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Phio...
06/25/2025 14:43:29

HC Wainwright & Co. analyst Joseph Pantginis reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price tar...

phio-pharmaceuticals-announced-that-the-safety-monitoring-committee-recommended-dose-escalation-in-its-phase-1b-clinical-trial-of-intratumoral-ph-762-in-the-treatment-of-stages-1-2-and-4-cutaneous-squamous-cell-carcinoma-stage-4-melanoma-and-stage-4-merkel-cell-carcinoma
Phio Pharmaceuticals Announced That The Sa...
06/25/2025 11:49:15

1-phio-pharma-ceo-to-present-new-skin-cancer-data-on-groundbreaking-gene-silencing-therapy-ph-762
1. Phio Pharma CEO To Present New Skin Can...
06/24/2025 11:47:05

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
06/05/2025 17:06:23

hc-wainwright--co-assumes-phio-pharma-at-buy-announces-price-target-of-14
HC Wainwright & Co. Assumes Phio Pharma at...
06/05/2025 11:11:13

HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Tar...

phio-pharma-to-present-update-on-proprietary-intasyl-sirna-technology-and-progress-on-on-going-clinical-trial-with-lead-compound-ph-762-for-treatment-of-skin-cancers
Phio Pharma To Present Update On Proprieta...
05/19/2025 11:50:47

Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Cor...

phio-pharma-q1-eps-047-down-from-041-yoy
Phio Pharma Q1 EPS $(0.47) Down From $(0.4...
05/15/2025 20:46:10

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.47) per share. This is a 14.63 percent decrease over losses of $(0.4...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/07/2025 17:06:24

phio-pharma-announces-pathology-results-in-third-dose-cohort-in-intasyl-ph-762-skin-cancer-clinical-trial
Phio Pharma Announces Pathology Results In...
05/07/2025 11:47:29

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing r...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION